IRIS
VENDITTI, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 66.625
EU - Europa 7.145
AS - Asia 3.746
SA - Sud America 145
AF - Africa 58
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 22
Totale 77.781
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 66.551
DE - Germania 1.764
IT - Italia 1.759
SG - Singapore 1.501
CN - Cina 1.036
UA - Ucraina 903
IE - Irlanda 749
RU - Federazione Russa 558
HK - Hong Kong 496
GB - Regno Unito 397
KR - Corea 309
FR - Francia 303
FI - Finlandia 223
SE - Svezia 164
BR - Brasile 103
NL - Olanda 81
IN - India 64
ID - Indonesia 57
JP - Giappone 55
CA - Canada 51
BE - Belgio 38
EG - Egitto 38
AU - Australia 36
PL - Polonia 36
AT - Austria 35
UZ - Uzbekistan 29
ES - Italia 28
IR - Iran 28
VN - Vietnam 28
PH - Filippine 24
CH - Svizzera 20
TH - Thailandia 20
CZ - Repubblica Ceca 18
MX - Messico 18
PK - Pakistan 18
PE - Perù 16
TR - Turchia 15
EU - Europa 14
RO - Romania 12
IQ - Iraq 11
CL - Cile 9
MY - Malesia 9
TW - Taiwan 9
AR - Argentina 8
SA - Arabia Saudita 8
A2 - ???statistics.table.value.countryCode.A2??? 7
PT - Portogallo 7
DK - Danimarca 5
GR - Grecia 5
IL - Israele 5
KG - Kirghizistan 5
RS - Serbia 5
BG - Bulgaria 4
BJ - Benin 4
LT - Lituania 4
LU - Lussemburgo 4
MA - Marocco 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
VE - Venezuela 4
AL - Albania 3
BD - Bangladesh 3
CR - Costa Rica 3
LK - Sri Lanka 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
BH - Bahrain 2
CO - Colombia 2
DM - Dominica 2
EC - Ecuador 2
EE - Estonia 2
HR - Croazia 2
HU - Ungheria 2
MC - Monaco 2
MD - Moldavia 2
QA - Qatar 2
SD - Sudan 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
FJ - Figi 1
GE - Georgia 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MM - Myanmar 1
PS - Palestinian Territory 1
SC - Seychelles 1
SN - Senegal 1
TN - Tunisia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 77.781
Salva come PNG Salva come JPEG
Città #
Woodbridge 19.662
Wilmington 17.896
Houston 14.958
Fairfield 2.156
Ann Arbor 1.562
Chandler 1.429
Singapore 1.303
Ashburn 1.083
Seattle 855
Jacksonville 801
Cambridge 751
Dublin 691
Dearborn 528
Medford 497
Hong Kong 477
Rome 463
New York 384
Beijing 356
Santa Clara 324
Lawrence 232
Zhengzhou 213
Milan 205
Boardman 120
San Diego 105
Moscow 98
Menlo Park 83
Mülheim 81
Redwood City 77
Council Bluffs 75
Creede 69
Shanghai 61
Engelhard 59
Hefei 56
London 55
Jakarta 51
Nanjing 50
Bologna 41
Nuremberg 40
Norwalk 39
University Park 37
Munich 36
Guangzhou 34
Brussels 33
Florence 33
Kunming 32
Falls Church 30
Los Angeles 30
Helsinki 29
Mountain View 29
Center 28
Verona 27
Palo Alto 26
Seoul 25
Lappeenranta 23
Naples 23
Toronto 23
Nürnberg 20
Turin 20
Chicago 19
Dong Ket 19
Saint Petersburg 19
Hangzhou 18
Brno 17
Kraków 17
Nanchang 17
Phoenix 17
Bari 14
Redmond 14
Lima 13
Paris 13
San Francisco 13
Tokyo 13
Del Norte 12
Frankfurt am Main 12
Hebei 12
Jinan 12
Kilburn 12
Manila 12
Shenyang 12
Bang Bai Mai 11
Hounslow 11
Pescara 11
Roebling 11
Vienna 11
Fuzhou 10
Padova 10
Pune 10
San Mateo 10
São Paulo 10
Brooklyn 9
Catania 9
Chiswick 9
Groningen 9
Mumbai 9
Palermo 9
Amsterdam 8
Detroit 8
Giza 8
Madrid 8
Wuhan 8
Totale 69.030
Salva come PNG Salva come JPEG
Nome #
La leucemia mieloide acuta nell’anziano. 922
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 611
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 558
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 480
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 470
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 463
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 458
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 456
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 454
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 452
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 451
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 449
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 447
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 442
Red blood cell depletion of cord blood using hydroxyethylstarch double sedimentation: analysis of 40 cases 441
Clinical significance of CD38 expression in chronic lymphocytic leukemia 440
CD7 expression in acute myeloid leukemia 440
All-trans-retinoic acid plus low-doses of cytarabine for the treatment of poor-risk acute myeloid leukemias 439
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 437
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 436
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 435
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 433
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 432
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 432
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 431
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 430
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 430
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 429
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 429
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 426
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 426
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 425
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 425
Leukocyte alkaline-phosphatase score in plasma-cell dyscrasias - correlation with disease severity and circulating levels of granulocyte-colony-stimulating factor 424
Acute megakaryoblastic leukemia: experience of GIMEMA trials 423
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 423
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 419
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 418
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 417
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 417
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 416
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making 415
Biological features of acute myeloid leukemia in the elderly 415
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. 414
CD7 Expression in acute myeloid leukemia 413
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 413
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 411
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 411
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 409
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 408
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 408
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 408
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 407
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 407
First report of t(8;21)(q22;q22) in a case of de novo acute monoblastic leukemia 407
Diagnosis of acute myeloid leukemia and system Coulter VCS 406
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 405
AML-M0: a biological and clinical profile 403
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 402
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 397
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 395
Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0) 394
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 392
Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program. 391
High interleukin-6 plasma levels in acute promyelocytic leukemia 391
A haematology consensus agreement on antifungal strategies for neutropenic patients with haematological malignancies and stem cell transplant recipients 390
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 390
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 388
Clinical heterogeneity of idiopathic CD4+T lymphocytopenia 388
Azacitidine for the treatment of patients with acute myeloid leukemia 387
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 387
Biological pattern of AML-M0 versus AML-M1: Response 386
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 386
Blood stem cell processing 385
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 384
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 384
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 384
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 383
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 382
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 382
Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis 381
P-glycoprotein expression in de novo acute myeloid leukemia 381
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia 381
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 380
Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera 380
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 380
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 379
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 378
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 377
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 377
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 377
Recurrence of a t(8;21)-positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge 376
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm 374
Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (M0) 373
Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery 372
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia 372
Two novel methods for rapid detection and quantification of DNMT3A R882 mutations in acute myeloid leukemia 371
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 370
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia 369
Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo cases 366
Totale 41.708
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.167
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171.167
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.558 0 0 0 0 0 0 0 1.760 1.677 1.630 1.155 1.336
2020/202111.567 1.268 1.326 1.177 1.613 1.225 1.186 1.464 1.057 334 325 442 150
2021/20222.685 106 308 88 102 77 248 145 165 213 236 207 790
2022/20233.956 415 307 291 410 264 756 483 242 450 70 187 81
2023/20242.259 178 84 201 84 256 553 139 143 98 72 106 345
2024/20254.384 285 1.470 789 413 194 432 552 249 0 0 0 0
Totale 78.779